Skip to main content

HIV/AIDS

Featured Article
“Estimating the lifetime costs of managing HIV is useful for budgetary planning and to ensure HIV management is affordable for all,” the study concluded.
Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre…

Insights

Han-Zhu Qian, MD, PhD, MPH, explains the importance of screening cognitive functions and identifying the domains of cognitive impairment by age group among people living with HIV.
Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre-clinical and clinical assessment of latency…
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational…
While great strides have been made in treating people with HIV over the past few decades, the US Preventive Task Force is strongly recommending PrEP for anyone at risk to help prevent the spread of the disease with which approximately 1.1 million…

Interactive Features

Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide…
Back to Top